Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs GoodRx

GOAL.MD
Graded #151

Lower grade

vs+1.1999999999999886
GoodRx
Graded #125

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 68.4/100, but only just.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. GOAL.MD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +16
64
80
Dose & formulationGOAL.MD +16
86
70
Clinical oversightGoodRx +1
68
69
Labs & monitoringGOAL.MD +2
53
51
FulfillmentGoodRx +4
77
81
Contract termsEven
55
55
GOAL.MD · left barGoodRx · right bar

The numbers

MetricGOAL.MDGoodRx
WeighScore68.4/10069.6/100
GradeCC
Scorecard rank#151#125
Semaglutide$179/moNot disclosed
Tirzepatide$249/mo (starting dose, compounded)$299/mo (brand Zepbound)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
GOAL.MD

Graded #151 · C

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation
GoodRx

Graded #125 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard